Immunotherapy最新文献

Neoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report. 新辅助免疫治疗孤立性腹膜间皮瘤累及腹壁：一例报告。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-07-21 DOI: 10.1080/1750743X.2025.2535941

Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano

引用次数: 0

Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. 胰腺癌立体定向放射治疗加过继性vNKT细胞治疗：II期试验方案。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-07-16 DOI: 10.1080/1750743X.2025.2533112

Xiaofei Zhu, Xiaolan Yin, Wenyu Liu, Chunshan Yu, Sheng Xia, Yangsen Cao, Lingong Jiang, Zhenhong Guo, Minghui Zhang, Huojun Zhang

{"title":"Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial.","authors":"Xiaofei Zhu, Xiaolan Yin, Wenyu Liu, Chunshan Yu, Sheng Xia, Yangsen Cao, Lingong Jiang, Zhenhong Guo, Minghui Zhang, Huojun Zhang","doi":"10.1080/1750743X.2025.2533112","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2533112","url":null,"abstract":"Aims: Novel and multimodal immunotherapy approaches are required for pancreatic cancer. A novel subset of NKT cells, called CD8+ NKT-like cells or variant NKT (vNKT) cells, which are CD8+ CD56+, CD1d-independent with variant TCR, have been reported to provide potent anti-tumor immunity. With positive immune regulations of stereotactic body radiation therapy (SBRT) reported in previous studies, we hypothesize that there might be a synergy of SBRT with immunotherapy. The aim of this study is to evaluate the efficacy and safety of SBRT plus vNKT cells as adoptive cell therapy for advanced pancreatic cancer.Methods: The prescription dose of SBRT ranges from 35 to 40 Gy/5f. Transfer of allogeneic vNKT cells is initiated 1-2 weeks after SBRT. Patients receive transfusion of vNKT cells twice a month with a 12-24 h interval within 6 months after SBRT and once a month thereafter. A 12-month transfer is defined as a cycle. The primary outcome is overall survival. The secondary outcomes are progression-free survival, adverse events, and quality of life.Conclusion: Therapeutic potential of SBRT plus vNKT cells may provide a novel insight into the treatment for advanced pancreatic cancer, and further investigations on the clinical benefits compared to standard chemoradiotherapy are warranted.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05783076.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nivolumab induced discolouration of the tongue: a case report. 纳武单抗引起的舌头变色：1例报告。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-07-13 DOI: 10.1080/1750743X.2025.2533105

Elif Değirmenci Aktaş, Dilek Yildirim

引用次数: 0

Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review. 结直肠癌患者免疫检查点抑制的预测性生物标志物：综合综述

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-07-12 DOI: 10.1080/1750743X.2025.2530853

Ibrahim Halil Sahin, Turcin Saridogan, Richard Kim

{"title":"Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review.","authors":"Ibrahim Halil Sahin, Turcin Saridogan, Richard Kim","doi":"10.1080/1750743X.2025.2530853","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2530853","url":null,"abstract":"Immune checkpoint inhibitors have resulted in treatment paradigm changes for the management of patients with solid tumors, including microsatellite instability-high (MSI-H) colorectal cancer (CRC). Although the benefit of these agents appears to be limited for microsatellite stable (MSS) CRC, recent studies suggest that the immune microenvironment of the early-stage MSS CRC and perhaps those with advanced-stage disease without active liver metastasis may be more immune permissive where relatively more promising responses were noted. At this time, biomarkers of immunotherapy for patients with CRC have not been well-defined. Except for the loss of mismatch repair protein (MMR) function and POLE/POLD1 mutations, most of the biomarkers of response are largely investigational. In this review article, we summarize recent research and drug development with immune checkpoint inhibitors for patients with MSS and MSI-H CRC and elaborate on investigational biomarkers, including but not limited to tumor mutation burden and immunoscore. We also discuss the relevance and potential applicability of these biomarkers to clinical practice for the use of immune checkpoint inhibitors and provided further perspective on future biomarker development.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.7,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection. 用T淋巴细胞和B淋巴细胞耗竭治疗免疫检查点抑制剂相关的移植排斥反应。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-07-06 DOI: 10.1080/1750743X.2025.2529152

Siqi Qiu, Zhipeng Zong, Kang He

引用次数: 0

Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors. 血清白蛋白-肌酐比值作为免疫检查点抑制剂治疗患者的生物标志物的预后价值

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-05 DOI: 10.1080/1750743X.2025.2513850

Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar

{"title":"Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors.","authors":"Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar","doi":"10.1080/1750743X.2025.2513850","DOIUrl":"10.1080/1750743X.2025.2513850","url":null,"abstract":"Background: Albumin and creatinine are considered important for understanding patient response to immune checkpoint inhibitors (ICIs). However, numerous confounding factors complicate the interpretation of albumin and creatinine alone in clinical practice. This study aims to assess the correlation between survival outcomes and serum-albumin creatinine ratio (sACR) in patients treated with ICIs.Methods: This study was conducted on individuals who received at least three doses of ICI between 2018 and 2023. Patients were divided into two groups, sACR-High and sACR-Low, based on the median level. The relationship between sACR and survival outcomes was analyzed using a cox regression model. The relationship between sACR and early progression, late progression, and long-term benefit was analyzed using a logistic regression model.Results: Patients with lower sACR had decreased overall survival (OS) (HR: 1.42, 95% CI 1.07-1.89, p = 0.014) and progression-free survival (PFS) (HR: 1.34, 95% CI 1.08-1.66, p = 0.009). sACR was associated with early progression (HR: 1.86, 95% CI, 1.14-3.01, p = 0.012), late progression (HR: 2.06, 95 % CI 1.0-4.24, p = 0.050), and long-term benefit of ICIs (HR: 1.72, 95% CI 1.002-2.93, p = 0.049).Conclusions: Our study demonstrated that sACR could serve as an independent predictor of OS, PFS, early progression, late progression, and long-term benefit in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"567-575"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies. Pegcetacoplan用于治疗因年龄相关性黄斑变性引起的地理萎缩：OAKS和DERBY临床研究的简单语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-01-17 DOI: 10.1080/1750743X.2025.2449760

Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, David Boyer, Federico Grossi, Caroline R Baumal, Jean-Francois Korobelnik, Jason S Slakter, Nadia K Waheed, Ravi Metlapally, Ian Pearce, Nathan Steinle, Anibal A Francone, Allen Hu, David R Lally, Pascal Deschatelets, Cedric Francois, Caleb Bliss, Giovanni Staurenghi, Jordi Monés, Rishi P Singh, Ramiro Ribeiro, Charles C Wykoff

引用次数: 0

Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors. 白蛋白-肌骨化症作为免疫检查点抑制剂治疗患者的预后生物标志物。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-27 DOI: 10.1080/1750743X.2025.2525743

Taha Koray Sahin, Deniz Can Guven, Yakup Ozbay, Firat Atak, Sevtap Arslan, Mehmet Cihan İcli, Latif Karahan, Yunus Kaygusuz, Zafer Arik, Omer Dizdar, Mustafa Erman, Suayib Yalcin, Mehmet Ruhi Onur, Sercan Aksoy

{"title":"Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors.","authors":"Taha Koray Sahin, Deniz Can Guven, Yakup Ozbay, Firat Atak, Sevtap Arslan, Mehmet Cihan İcli, Latif Karahan, Yunus Kaygusuz, Zafer Arik, Omer Dizdar, Mustafa Erman, Suayib Yalcin, Mehmet Ruhi Onur, Sercan Aksoy","doi":"10.1080/1750743X.2025.2525743","DOIUrl":"10.1080/1750743X.2025.2525743","url":null,"abstract":"Background: Although immune checkpoint inhibitors (ICIs) have heralded a new era in cancer treatment, many patients do not respond, underscoring the need for biomarkers. The albumin-myosteatosis gauge (AMG) is a recently developed integrated measure of myosteatosis and serum albumin levels, reflecting systemic inflammation and malnutrition. Herein, we investigate the prognostic value of AMG in patients with advanced cancer treated with ICIs.Methods: A total of 308 patients with advanced cancer treated with ICIs were included. Skeletal muscle index and skeletal muscle radiodensity (SMD) were measured from computed tomography images obtained at the level of the L3 vertebra. The AMG was calculated by multiplying SMD by albumin and expressed as an arbitrary unit.Results: The median age (interquartile range) was 63 (55-70), and 198 (64.3%) were male. Non-small cell lung cancer (NSCLC) was the most common primary cancer (28.2%), followed by RCC (20.8%) and melanoma (20.2%). Multivariable analyses revealed that lower AMG values were independently associated with decreased OS (HR:1.37; 95%CI:1.03-1.82; p = 0.032) and PFS (HR:1.39; 95% CI:1.07-1.79;p = 0.012) compared to the AMG high-group.Conclusion: Our findings suggest AMG, an easily accessible novel biomarker, is an independent prognostic factor for survival in patients with advanced cancer treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"657-665"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging of brain metastases treated with immune checkpoint inhibitors. 免疫检查点抑制剂治疗脑转移瘤的影像学研究。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1080/1750743X.2025.2501931

Imren Özdamar, Sophie H A E Derks, Astrid A M van der Veldt

引用次数: 0

Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report. 埃夫加替莫德治疗派姆单抗诱导的心肌炎、肌炎和重症肌无力重叠综合征（IM3OS） 1例

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI: 10.1080/1750743X.2025.2517522

Stephanie S Cobelas-Cartagena, Emilio Amigo-Otero, Victoria García-Samblas, Jesus Flores-Raposo, Silvia Rodrigo-Herrero, Juan Bayo-Calero

引用次数: 0